Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06433180

Study of Fecal Microbiota Transplantation (FMT) in Severe IBS Patients

The objective of this protocol is to evaluate the efficacy of fecal microbiota transplantation (FMT) using oral capsules containing frozen stools vs sham FMT on IBS severity score at 12 weeks in patients with severe irritable bowel syndrome refractory to conventional treatments.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Irritable Bowel Syndrome Colonic Diseases Colonic Diseases, Functional Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

About this study

Irritable bowel syndrome (IBS) is a chronic disease. It affects about 4.4 to 10 % of the French general population (according to Rome III or Rome IV definition) and is the most frequent functional bowel disorder in patients visiting general practitioners or gastroenterologists. The efficacy of treatments is often limited, in particular form the case severe of IBS (IBS-SSS>300) which concerns at least 20 to 25% of patients and IBS can cause significant deterioration in quality of life.

In this context, microbiota could become a potential therapeutic target, and replacement of the abnormal fecal microbiota by an "healthy" one, especially in patients refractory to previous treatment and with severe symptoms, is a seducing new therapeutic strategy. The primary outcome is an improvement in the IBS-SSS score level at 12 weeks after taking a oral capsules of FMT in patients with severe IBS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years and < 75 years
  • IBS defined according to Rome IV definition (IBS-C, IBS-D or IBS-M)
  • Severe disease (IBS-SSS >300) and refractory to at least two previous treatment strategies:among the following : anti-spasmodic and/or laxatives (polyethylene glycol) or anti-diarrheal drug (loperamide) according to transit subtype for one month, antidepressants for 2 months, probiotics (ALFLOREX, SMEBIOCTA, PROBIOLOG FLORVIS) for 1 month, hypnosis for 5 hypnosis sessions in two months, Cognitive Behavioral Therapies for 2 months, colestyramine for IBS-D patients for 1 month, ondansetron for IBS-D patients and for 1 month, ebastine for 2 months, L-glutamine (5g x3/day, for 2 months, Gelsectan for one month, Biofeedback for 15 sessions in IBS-C (3 months), Low FODMAP diet for 1 month, gluten free diet for 1 month, standard dietary advice from the NICE (UK) for 1 month, increase in physical activity.
  • Patient with health insurance (AME excepted)
  • Informed written consent
  • For women with childbearing potential, efficient contraception for the duration of the participation to the study

Exclusion criteria

  • Other chronic gastrointestinal disease (celiac disease, inflammatory bowel disease)
  • participants if there is a reason to suspect an alternative diagnosis to the IBS complaints
  • Surgical intervention in the gastrointestinal region except for appendectomy, hernia repair, cholecystectomy and hemorroidectomy
  • Treatment preceding FMT with: antibiotics, antifungic or probiotics treatment < 4 weeks, or factors that may affect the composition of intestinal microbiota
  • Abuse of alcohol or drugs
  • Pregnancy or breastfeeding
  • Participation in any other interventional study
  • Patients under legal protection.
  • Acute COVID-19 infection
  • Presence of systemic disease, immune deficiency or treatment with immune-modulators
  • Severe psychiatric disorder
  • Participants who were assessed as likely to be noncompliant (ie, not adhering to the tasks they were to perform as participants)

Treatment and study plan

Administration of fecal microbiota transplantation ( FMT capsules)

Drug

Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.

Administration of the sham (PLACEBO)

Drug

Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.

Primary outcomes

  1. Decrease in IBS severity at 12 weeks defined by the percentage of patients having at least a 75 points decrease in IBS-SSS.

    Time frame: At 12 weeks

    To evaluate the efficacy of oral capsules containing frozen fecal microbiota (FMT) vs sham FMT on IBS severity score at 12 weeks in patients with irritable bowel syndrome with severe disease refractory to conventional treatments.

    Decrease in IBS severity at 12 weeks is defined by the percentage of patients having at least a 75 points decrease in IBS-SSS.

Secondary outcomes

  1. Decrease in IBS severity at 12 weeks defined by the percentage of patients having at least a 50 points decrease in IBS-SSS.

    Time frame: At 12 weeks

    To evaluate the efficacy of oral capsules containing frozen fecal microbiota (FMT) vs sham FMT on IBS severity score at 12 weeks in patients with irritable bowel syndrome with severe disease refractory to conventional treatments (at least a 50 points decrease in IBS-SSS)

  2. FMT success

    Time frame: At 12 weeks

    patient's microbiota 12 weeks after FMT closer to that of the donor than the patient's microbiota before FMT. The composition of the patient's fecal microbiota 12 weeks after FMT will be compared to the patient's microbiota before transplantation and to the donor using the Sorensen similarity index. The FMT will be considered as a success if the Sorensen index [patient after FMT vs donor] > Sorensen index [patient after FMT vs patient before FMT] and if the Sorensen index [patient after FMT vs donor] ≥ 0,6. The composition of fecal microbiota will be measured by pyrosequencing (16S RNA).

  3. Intestinal microbiota composition at week 12 and 24 by 16s sequencing.

    Time frame: at week 12 and 24

    Intestinal microbiota composition and diversity at week 12 and 24 assessed by 16s sequencing. Microbiota composition and diversity assessed by 16s sequencing at week 12 and 24, compared to baseline and to healthy volunteers donor's microbiota. Microbiota composition will be assessed using Qiime pipeline and analyzed at all phylogenetic levels.

    Diversity will be evaluated using Shannon index, Simpson index, Chao1 index and number of observed species.

  4. Efficacy (decrease in IBS severity >75 points) at week 24 according to FMT success.

    Time frame: At 24 weeks

    Efficacy (decrease in IBS severity >75 points) according to FMT success.

  5. EMA Endpoint at week 12 and 24 defined as a patient who fulfils the response criteria (simultaneous improvement of transit and abdominal pain) displayed in the following for at least 50% of the observation time.

    Time frame: at week 12 and 24

    Efficacy according to EMA (European Medical Agency) endpoint in IBS on composite criteria at 12 or 24 weeks

  6. Percentage of responders in the different subgroups IBS-D, IBS-C and IBS-M using the primary endpoint at week 12 and 24.

    Time frame: at week 12 and 24

    IBS severity at 12 weeks by donors (one donor giving FMT to several patients)

  7. Mean IBS-SSS (IBS severity), comparison between FMT and placebo at 12 and 24 weeks)

    Time frame: at week 12 and 24

    IBS severity at 12 weeks and at 24 weeks by IBS subtypes according to transit pattern.

    The score ranges from 0 to 500 ( Remission : 0 to 74, Mild : 75 to 175, Moderate : 175 to 300 and Severe : >300).

  8. Mean IBS-QoL score (IBS Quality of life) comparison between FMT and placebo at 12 and 24 weeks (Drossman et al. 2000)

    Time frame: at week 12 and 24

    IBS Quality of life at 12 weeks and 24 weeks. Irritable Bowel Syndrom- Quality of Life (IBS-QoL) at 12 weeks and 24 weeks, IBS-QoL ranges from 0 ( worse) to 100 (better).

  9. Patient's perception of FMT : - Questionnaire for correct assessment of FMT or placebo and FMT acceptability) at V2 (FMT administration). - Questionnaire for assessment of FMT secondary effects at V3.

    Time frame: V2: five weeks after inclusion. V3:Four weeks after V2

    Patient's perception of FMT (questionnaire for correct assessment of FMT or placebo and FMT acceptability) (Annex D), secondary effects of FMT

  10. Safety (Serious Adverse Events, Adverse Events) compared between groups.

    Time frame: through study completion, at 24 months

    Safety (Serious Adverse Events, Adverse Events) compared between groups.

Study contacts

Contact information is provided by the study sponsor or research team.

Jean Marc SABATE, Pr

CONTACT

[email protected]

01 48 95 54 34

Nacira DARGHAL, PhD

CONTACT

[email protected]

01 48 95 74 73

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

A Prospective, Multi-center, Double Blind Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule Versus Placebo in Severe Irritable Bowel Syndrome (IBS).

Acronym: ICEBOAT

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
May 29, 2024
Registry last updated
Jun 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.